Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The treatment landscape for neuromyelitis optica spectrum disorder (NMOSD) has changed in recent years with the approval of therapies with different efficacy, safety and administration profiles. OBJECTIVE: The aim of this study was to assess neurologists' preferences for different NMOSD treatment attributes using conjoint analysis (CA). METHODS: We conducted an online, non-interventional, cross-sectional study in collaboration with the Spanish Society of Neurology. Our CA assessed five drugs' attributes: prevention of relapse, prevention of disability accumulation, safety risk, management during pregnancy, and route and frequency of administration. Participants were presented with eight hypothetical treatment scenarios to rank based on their preferences from the most preferred to the least. An ordinary least squares method was selected to estimate weighted preferences. RESULTS: A total of 104 neurologists were included. Mean age (standard deviation-SD) was 37.7 (10.3) years, 52.9 % were male, and median time (interquartile range) of experience managing NMOSD was 5.0 (2.9, 10.8) years. Neurologists placed the greatest importance on efficacy attributes, time to relapse (44.1 %) being the most important, followed by preventing disability accumulation (36.8 %). In contrast, route and frequency of administration (4.6 %) was the least important characteristic. Participants who prioritised efficacy attributes felt more comfortable in decision-making, had fewer past experiences of care-related regret and a lower attitude to risk taking than their counterparts. CONCLUSION: Neurologists' treatment preferences in NMOSD were mainly driven by efficacy attributes. These results may be useful to design policy decisions and treatment guidelines for this condition.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain
- Date Crossref
- 01/08/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital Clínico Universitario de Valladolid Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Roche (Spain) pays non établi dans la noticeEntreprise
-
Hospital Clínic de Barcelona Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Fundación Jiménez Díaz Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Virgen del Rocío Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Hospital de Cruces pays non établi dans la noticeÉtablissement de santé
-
University Hospital Complex Of Vigo pays non établi dans la noticeÉtablissement de santé
-
Vall d'Hebron Hospital Universitari pays non établi dans la noticeÉtablissement de santé
-
Instituto Químico Biológico pays non établi dans la noticeStructure de recherche
-
Medical Department pays non établi dans la noticeInstitution
-
Hospital Universitario Cruces Department of Neurology pays non établi dans la noticeÉtablissement de santé
-
Hospital Universitario Álvaro Cunqueiro Department of Neurology pays non établi dans la noticeÉtablissement de santé
Department of Neurology — Hospital Clínico Universitario de Valladolid, Roche (Spain) et Department of Neurology — Hospital Clínic de Barcelona, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.